Comparative Financials (Unaudited)

12 Months Ended

Dec. 31, 2018

Comparative Financial Information Disclosure [Abstract]

The Company changed its fiscal year end from July 31 to December 31 effective December 31, 2017. The unaudited consolidated results of operations for the year ended December 31, 2017 is as follows:



	For the Year Ended
(in thousands)	December 31, 2017
		(unaudited)
Revenue:
Royalty and licensing revenue	$	15,447
Treatment investment revenue		105
Grant and contract revenue		—
Total revenue		15,552
Operating expenses:
General and administrative		10,313
Research and development		4,857
Royalty expense		1,408
Selling expense		851
Total operating expenses		17,429
Income from operations		(1,877	)
Other income, net		68
Income before provision of income taxes		(1,809	)
Provision for income taxes		797
Net loss	$	(2,606	)